Effect of Clemastine on Neurophysiological Outcomes in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy

Bibliographic Data

ID15715919
AuthorsJana Krystofova Mike (0000-0002-0938-216X, University of California, San Francisco, corresponding author), Yasmine White (0000-0002-2708-7391, University of California, San Francisco), Rachel S Hutchings (0009-0008-1692-7122, University of California, San Francisco), Christian Vento (0000-0002-3131-7604, University of California, San Francisco), Janica Ha (0000-0003-2769-7824, University of California, San Francisco), Ariana Iranmahboub (University of California, San Francisco), Hadiya Manzoor (University of California, San Francisco), Anya Gunewardena (0009-0004-5510-2802, University of California, San Francisco), Cheryl Cheah (0000-0001-6031-7796, University of California, San Francisco), Aijun Wang (0000-0002-2985-5796, University of California, Davis), Brian D Goudy (University of California, Davis), Satyan Lakshminrusimha (0000-0001-6098-2155, University of California, Davis), Janel Long‐Boyle (University of California, San Francisco), Janel Long-Boyle (University of California, San Francisco), Jeffrey R Fineman (0000-0001-9740-405X, University of California, San Francisco), Donna M Ferriero (0000-0003-0560-9045, University of California, San Francisco), Emin Maltepe (0000-0002-1271-7565, University of California, San Francisco)
Year2023
Volume10
Issue11
Pages1728-1728
Publication date2023-10-25
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueChildren (JOURNAL)
Journal identifiersISSN: 2227-9067 • E-ISSN: 2227-9067
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/children10111728
PMID38002819
OpenAlexW4387940327
LanguageEN
Citations received1
References cited53

Originally approved by the U.S. Food and Drug Administration (FDA) for its antihistamine properties, clemastine can also promote white matter integrity and has shown promise in the treatment of demyelinating diseases such as multiple sclerosis. Here, we conducted an in-depth analysis of the feasibility, safety, and neuroprotective efficacy of clemastine administration in near-term lambs ( n = 25, 141-143 days) following a global ischemic insult induced via an umbilical cord occlusion (UCO) model. Lambs were randomly assigned to receive clemastine or placebo postnatally, and outcomes were assessed over a six-day period. Clemastine administration was well tolerated. While treated lambs demonstrated improvements in inflammatory scores, their neurodevelopmental outcomes were unchanged

Anesthesia · Cardiology · Encephalopathy · Hypoxia (environmental · Hypoxic-Ischemic Encephalopathy · Neonatal Encephalopathy · Neurophysiology · Oxygen · Psychiatry · Anesthesia and Neurotoxicity Research · Chemistry · Medicine · Metabolism and Genetic Disorders · Neonatal and fetal brain pathology · Neuroscience · Psychology · Internal Medicine

Tools

Open DOIOpen Access